{"created":"2023-05-15T15:01:44.282186+00:00","id":83743,"links":{},"metadata":{"_buckets":{"deposit":"7e79807a-bd02-429c-be79-97492b323a58"},"_deposit":{"created_by":1,"id":"83743","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"83743"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00083743","sets":["10:29"]},"author_link":["1009453","1009446","1009449","1009450","1009444","1009445","1009451","1009440","1009447","1009437","1009452","1009441","1009443","1009442","1009438","1009439","1009448"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2021-11-04","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"【目的】<SUP>64</SUP>Cu-ATSMは悪性腫瘍のPET診断に加えて治療への応用も期待され、現在本邦にて世界初の治療用量での医師主導臨床試験が進められている。我々は治療用量の<SUP>64</SUP>Cu-ATSMを安全に投薬可能で放射化学的にも安定な処方と、放射化学的収率の高い製造法の開発を行った。【方法・結果】治療用量での<SUP>64</SUP>Cu-ATSMの放射線分解を抑制するため、処方に含まれる安定化剤として15種類のラジカルスカベンジャーを検討した。L-アスコルビン酸ナトリウムを選択することにより、製造後24時間の安定性を担保可能であった。また、脂溶性の高い<SUP>64</SUP>Cu-ATSMを高い回収率で無菌ろ過するため、3種類のフィルターを検討した。ポリフッ化ビニリデン(PVDF) を用いることで、ろ過後の放射化学的収率が90%以上となった。更に、製剤中に含まれるATSM由来の分解産物についてLC-MSにより同定を行い、反応性の高い副反応物が生成していないことを確認した。【結論】本研究で開発した処方と製法との組み合わせにより、<SUP>64</SUP>Cu-ATSMを悪性腫瘍の治療に用いるための臨床評価を加速可能と期待できる。","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第61回日本核医学会学術総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"松本, 博樹"}],"nameIdentifiers":[{"nameIdentifier":"1009437","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"五十嵐, 千佳"}],"nameIdentifiers":[{"nameIdentifier":"1009438","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"橋本, 裕輝"}],"nameIdentifiers":[{"nameIdentifier":"1009439","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鈴木, 寿"}],"nameIdentifiers":[{"nameIdentifier":"1009440","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"河村, 和紀"}],"nameIdentifiers":[{"nameIdentifier":"1009441","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"張, 明栄"}],"nameIdentifiers":[{"nameIdentifier":"1009442","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"栗原, 宏明"}],"nameIdentifiers":[{"nameIdentifier":"1009443","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"東, 達也"}],"nameIdentifiers":[{"nameIdentifier":"1009444","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"吉井, 幸恵"}],"nameIdentifiers":[{"nameIdentifier":"1009445","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hiroki, Matsumoto","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1009446","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Chika, Igarashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1009447","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hiroki, Hashimoto","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1009448","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hisashi, Suzuki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1009449","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kazunori, Kawamura","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1009450","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Zhang, Ming-Rong","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1009451","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tatsuya, Higashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1009452","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yukie, Yoshii","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1009453","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"悪性腫瘍に対する臨床応用に向けた治療用量での64Cu-ATSMの製剤開発","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"悪性腫瘍に対する臨床応用に向けた治療用量での64Cu-ATSMの製剤開発"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-10-25"},"publish_date":"2021-10-25","publish_status":"0","recid":"83743","relation_version_is_last":true,"title":["悪性腫瘍に対する臨床応用に向けた治療用量での64Cu-ATSMの製剤開発"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T19:07:45.868317+00:00"}